Decreased efficacy of inhaled pentamidine in the prevention of Pneumocystis carinii pneumonia among HIV-infected patients with severe immunodeficiency

L. Casale, H. Gold, Clyde B. Schechter, A. Naficy, J. R. Masci

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Study Objective: To determine the relationship between the degree of immune deficiency and the risk of Pneumocystis carinii pneumonia (PCP) among HIV-infected patients receiving inhaled pentamidine prophylaxis. Design: Retrospective chart review. Setting: AIDS clinic of inner-city hospital. Patients: Patients attending inhaled pentamidine clinic between 1989 and 1991. Intervention: Review of medical records of patients receiving inhaled pentamidine, 300 mg/month, via nebulizer (Respirgard II) as primary or secondary prophylaxis of PCP. Statistical analysis of lymphocyte subset results and selected clinical data. Results: Ten of 57 patients developed PCP during the period of analysis. Patients with CD4 counts less than 60/mm3 were significantly more likely to develop PCP (p=0.01; Fisher's exact test) with a relative risk of 7.55 compared to patients with CD4 lymphocyte counts greater than 60/mm3. Conclusion: Failure of inhaled pentamidine prophylaxis is seen almost exclusively among patients with CD4 lymphocyte counts below 60/mm3.

Original languageEnglish (US)
Pages (from-to)342-344
Number of pages3
JournalChest
Volume103
Issue number2
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Pentamidine
Pneumocystis Pneumonia
HIV
CD4 Lymphocyte Count
Nebulizers and Vaporizers
Urban Hospitals
Lymphocyte Subsets
Medical Records
Acquired Immunodeficiency Syndrome
Demography

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Decreased efficacy of inhaled pentamidine in the prevention of Pneumocystis carinii pneumonia among HIV-infected patients with severe immunodeficiency. / Casale, L.; Gold, H.; Schechter, Clyde B.; Naficy, A.; Masci, J. R.

In: Chest, Vol. 103, No. 2, 01.01.1993, p. 342-344.

Research output: Contribution to journalArticle

@article{fb8d15d5f9e44e1eb4b2b62645d4b9e0,
title = "Decreased efficacy of inhaled pentamidine in the prevention of Pneumocystis carinii pneumonia among HIV-infected patients with severe immunodeficiency",
abstract = "Study Objective: To determine the relationship between the degree of immune deficiency and the risk of Pneumocystis carinii pneumonia (PCP) among HIV-infected patients receiving inhaled pentamidine prophylaxis. Design: Retrospective chart review. Setting: AIDS clinic of inner-city hospital. Patients: Patients attending inhaled pentamidine clinic between 1989 and 1991. Intervention: Review of medical records of patients receiving inhaled pentamidine, 300 mg/month, via nebulizer (Respirgard II) as primary or secondary prophylaxis of PCP. Statistical analysis of lymphocyte subset results and selected clinical data. Results: Ten of 57 patients developed PCP during the period of analysis. Patients with CD4 counts less than 60/mm3 were significantly more likely to develop PCP (p=0.01; Fisher's exact test) with a relative risk of 7.55 compared to patients with CD4 lymphocyte counts greater than 60/mm3. Conclusion: Failure of inhaled pentamidine prophylaxis is seen almost exclusively among patients with CD4 lymphocyte counts below 60/mm3.",
author = "L. Casale and H. Gold and Schechter, {Clyde B.} and A. Naficy and Masci, {J. R.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1378/chest.103.2.342",
language = "English (US)",
volume = "103",
pages = "342--344",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2",

}

TY - JOUR

T1 - Decreased efficacy of inhaled pentamidine in the prevention of Pneumocystis carinii pneumonia among HIV-infected patients with severe immunodeficiency

AU - Casale, L.

AU - Gold, H.

AU - Schechter, Clyde B.

AU - Naficy, A.

AU - Masci, J. R.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Study Objective: To determine the relationship between the degree of immune deficiency and the risk of Pneumocystis carinii pneumonia (PCP) among HIV-infected patients receiving inhaled pentamidine prophylaxis. Design: Retrospective chart review. Setting: AIDS clinic of inner-city hospital. Patients: Patients attending inhaled pentamidine clinic between 1989 and 1991. Intervention: Review of medical records of patients receiving inhaled pentamidine, 300 mg/month, via nebulizer (Respirgard II) as primary or secondary prophylaxis of PCP. Statistical analysis of lymphocyte subset results and selected clinical data. Results: Ten of 57 patients developed PCP during the period of analysis. Patients with CD4 counts less than 60/mm3 were significantly more likely to develop PCP (p=0.01; Fisher's exact test) with a relative risk of 7.55 compared to patients with CD4 lymphocyte counts greater than 60/mm3. Conclusion: Failure of inhaled pentamidine prophylaxis is seen almost exclusively among patients with CD4 lymphocyte counts below 60/mm3.

AB - Study Objective: To determine the relationship between the degree of immune deficiency and the risk of Pneumocystis carinii pneumonia (PCP) among HIV-infected patients receiving inhaled pentamidine prophylaxis. Design: Retrospective chart review. Setting: AIDS clinic of inner-city hospital. Patients: Patients attending inhaled pentamidine clinic between 1989 and 1991. Intervention: Review of medical records of patients receiving inhaled pentamidine, 300 mg/month, via nebulizer (Respirgard II) as primary or secondary prophylaxis of PCP. Statistical analysis of lymphocyte subset results and selected clinical data. Results: Ten of 57 patients developed PCP during the period of analysis. Patients with CD4 counts less than 60/mm3 were significantly more likely to develop PCP (p=0.01; Fisher's exact test) with a relative risk of 7.55 compared to patients with CD4 lymphocyte counts greater than 60/mm3. Conclusion: Failure of inhaled pentamidine prophylaxis is seen almost exclusively among patients with CD4 lymphocyte counts below 60/mm3.

UR - http://www.scopus.com/inward/record.url?scp=0027479615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027479615&partnerID=8YFLogxK

U2 - 10.1378/chest.103.2.342

DO - 10.1378/chest.103.2.342

M3 - Article

C2 - 8094333

AN - SCOPUS:0027479615

VL - 103

SP - 342

EP - 344

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2

ER -